Phthalazinone-based lactams and cyclic ureas as ROCK2 selective inhibitors.

[1]  J. Weiss,et al.  ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Wexler,et al.  Identification of 5H-Chromeno[3,4-c]pyridine and 6H-Isochromeno[3,4-c]pyridine Derivatives as Potent and Selective Dual ROCK Inhibitors. , 2020, Bioorganic & medicinal chemistry letters.

[3]  David S. Taylor,et al.  Discovery of a Phenylpyrazole Amide ROCK Inhibitor as a Tool Molecule for in vivo Studies. , 2020, Bioorganic & medicinal chemistry letters.

[4]  A. Ridley,et al.  The Function of Rho-Associated Kinases ROCK1 and ROCK2 in the Pathogenesis of Cardiovascular Disease , 2015, Front. Pharmacol..

[5]  G. Loirand.  Rho Kinases in Health and Disease: From Basic Science to Translational Research , 2015, Pharmacological Reviews.

[6]  J. Liao,et al.  The Rho Kinases: Critical Mediators of Multiple Profibrotic Processes and Rational Targets for New Therapies for Pulmonary Fibrosis , 2015, Pharmacological Reviews.

[7]  H. Shimokawa,et al.  Crucial Role of ROCK2 in Vascular Smooth Muscle Cells for Hypoxia-Induced Pulmonary Hypertension in Mice , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[8]  Alice V. Schofield,et al.  Rho-associated coiled-coil kinase (ROCK) signaling and disease , 2013, Critical reviews in biochemistry and molecular biology.

[9]  Y. Hiroi,et al.  FHL2 prevents cardiac hypertrophy in mice with cardiac‐specific deletion of ROCK2 , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  M. Olson,et al.  Rho‐associated kinases in tumorigenesis: re‐considering ROCK inhibition for cancer therapy , 2012, EMBO reports.

[11]  A. Stepan,et al.  Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. , 2011, Chemical research in toxicology.

[12]  X. Zheng,et al.  ROCK Isoform Regulation of Myosin Phosphatase and Contractility in Vascular Smooth Muscle Cells , 2009, Circulation research.

[13]  Hiroaki Shimokawa,et al.  Development of Rho-kinase inhibitors for cardiovascular medicine. , 2007, Trends in pharmacological sciences.

[14]  T. Yamamoto,et al.  Rho‐associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. , 1996, The EMBO journal.

[15]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.